Clinical Trials and Research Studies
At NYU Langone Health, our doctors and researchers perform clinical trials and research studies with the aim of translating findings into new, more effective treatments.
Recently Added/Updated Trials
-
A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With Non-Muscle Invasive Bladder Cancer
This study is examining how well a new treatment called N-803, combined with a standard treatment called BCG, works compared to just using BCG alone ...
-
A First-in-Human Phase 1a/1b Trial to Assess the Safety Tolerability and Preliminary Efficacy of LY4170156 an Antibody-Drug Conjugate Targeting Folate Receptor a Expressing Tumor Cells in Participants with Selected Advanced Solid Tumors
This study will test a new drug called LY4170156, an antibody drug conjugate (ADC) to see how it works in the body, and if it ...
-
A Phase 1/1b First-In-Human Multi-Part Open-Label Study to Investigate the Safety Tolerability Pharmacokinetics Biological and Clinical Activity of DF6215 in Patients with Advanced (Unresectable Recurrent or Metastatic) Solid Tumors
This is a study is testing a new drug called DF6215 on patients with tough-to-treat (unresectable, recurrent or metastatic) solid tumors. The goal is to ...
-
Randomized Open-label Multicenter Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-na ve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
This is a study to compare two medicines (repotrectinib and crizotinib) for patients with a type of lung cancer called ROS1-positive NSCLC (Non-small Cell Lung ...
-
A Phase 2a Study with Safety Run-in to Evaluate the Safety Tolerability and Preliminary Efficacy of FF-10832 Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Tumors
This is a medical study testing a drug called FF-10832 alone and with another medicine called pembrolizumab for patients with advanced solid tumors. First, patients ...
-
A Phase 2 Multi Cohort Open Label Multi Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48 ADC) Alone and in Combination with Pembrolizumab in Subjects with Locally Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2
This research study is testing two treatments for a type of bladder cancer (Urothelial Carcinoma that expresses HER2) that has spread or is hard to ...
-
A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors That Express HER2
This study wants to see if a medicine called disitamab vedotin (designed to go straight to cancer cells and slow down or shrink the cancer ... -
A RANDOMIZED PHASE II TRIAL OF ADJUVANT NIVOLUMAB WITH OR WITHOUT CABOZANTINIB IN PATIENTS WITH RESECTED MUCOSAL MELANOMA
The study is designed to help patients with different stages of mucosal melanoma, a type of skin cancer. There are three groups, or arms, in ...
Volunteer Sign-up
Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.
